Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B- Cell Lymphoma (DLBCL)

被引：0
|
作者：
Alchidiac, Jessy [1 ,2 ]
Hueso, Thomas [1 ]
Massard, Christophe [1 ]
Ribrag, Vincent [1 ]
Michot, Jean-Marie [1 ]
机构：
[1] Inst Gustave Roussy, Paris, France
[2] Lebanese Univ, Beirut, Lebanon
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
ABCL; relapsed/refractory non-Hodgkin Lymphoma; CD20; loss; CD20 weak expression; biopsy at relapse;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-119
引用
收藏
页码：S457 / S457
页数：1
相关论文
共 50 条
  • [1] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    BLOOD, 2022, 140 : 7906 - 7907
  • [2] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [3] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Vukcevic, Mirko
    Yung, Mallory
    Khan, Mali
    Houpt, Bethany
    Schnell, Frederick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377
  • [5] The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)
    Lenz, Georg
    Rutherford, Sarah C.
    Davies, Andrew
    Zinzani, Pier Luigi
    Salles, Gilles
    Hasskarl, Jens
    Margunato-Debay, Sandra
    Rodrigues, Filipe
    Nientker, Lisette
    Balradj, Janita
    Alleman, Cathelijne
    BLOOD, 2018, 132
  • [6] Patient, caregiver, and physician preferences for treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Vukcevic, Mirko
    Yung, Mallory
    Khan, Maliha
    Schnell, Frederick Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18710 - E18710
  • [7] Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective
    Moertl, Bernhard
    Dreyling, Martin
    Schmidtl, Christian
    Hoster, Eva
    Schoel, Wolfgang
    V. Bergwelt-Baildon, Michael
    Berger, Karin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 474 - 482
  • [8] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [9] A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss
    Takiar, Radhika
    Ng, Wern Lynn
    Shah, Eshana
    Boonstra, Philip S.
    Karimi, Yasmin H.
    Carty, Shannon A.
    Wilcox, Ryan A.
    Zamalloa, Carlos A. Murga
    Nowakowski, Grzegorz S.
    Phillips, Tycel J.
    BLOOD, 2022, 140 : 9510 - 9511
  • [10] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    Van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Marie Jose
    Schuster, Stephen J.
    Salles, Gilles Andre
    Maziarz, Richard Thomas
    Anak, Oezlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    BLOOD, 2017, 130
12345